Zeng X M, Pandhal K H, Martin G P
Department of Pharmacy, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, UK.
Int J Pharm. 2000 Mar 20;197(1-2):41-52. doi: 10.1016/s0378-5173(99)00400-7.
Dry powder formulations for inhalation usually comprise a mixture of coarse lactose (CL), employed as a carrier, and micronized drug. It was the aim of this study to determine the effects of fine lactose (FL), blended as a tertiary component on the mixing homogeneity and dispersibility of a model hydrophobic drug, beclomethasone dipropionate (BDP). BDP particles (volume median diameter (VMD) 4.6 microm) existed mainly as agglomerates, the majority of which were not dispersed into primary particles after aerosolization at a high shear force (4.7 psi). The resultant particle size distribution of BDP was multi-modal with VMD varying between 4.7 and 30.2 microm. Ternary interactive mixtures were prepared to consist of CL, FL and BDP with a fixed ratio of lactose to BDP of 67.5:1 w/w, but two concentrations of FL, i.e. 2.5 and 5%, w/w. The mixing was carried out using different sequences of adding the three components for two mixing times (15 and 60 min). Binary mixtures composed of CL and BDP were prepared for both mixing times as the controls, and these exhibited a coefficient of variation (COV) in BDP content <= 5%. Addition of FL to the binary formulations greatly reduced the content uniformity of BDP if the final powder were prepared by first mixing CL with FL before mixing with the drug (COV>20%, after mixing for 15 min). However, the mixtures, prepared using other mixing sequences, had a similar uniformity of BDP content to the binary mixtures. All ternary mixtures containing 2.5% FL consistently produced a significantly higher (ANOVA P<0.01) fine particle fraction (FPF, 3.1--6.1%) and fine particle dose (FPD, 13.6--30.1 microg) of BDP than the binary mixtures (FPF, 0.3-0.4%; FPD, 1.6-2.1 microg) after aerosolization at 60 l min(-1) via a Rotahaler into a twin stage liquid impinger. The mixing sequences exerted a significant (P<0.05) effect on the dispersion and deaggregation of BDP from the formulations prepared using a mixing time of 15 min but such an effect disappeared when the mixing time was lengthened to 60 min. The dispersibility of BDP was always higher from the ternary mixtures than from the binary mixtures. BDP delivery from dry powder inhalers was improved markedly by adding FL to the formulation, without substantial reduction in the content uniformity of the drug.
吸入用干粉制剂通常包含用作载体的粗乳糖(CL)和微粉化药物的混合物。本研究的目的是确定作为第三组分混合的细乳糖(FL)对模型疏水药物二丙酸倍氯米松(BDP)混合均匀性和分散性的影响。BDP颗粒(体积中值直径(VMD)为4.6微米)主要以团聚体形式存在,在高剪切力(4.7 psi)雾化后,其中大部分未分散成初级颗粒。BDP的最终粒度分布呈多峰型,VMD在4.7至30.2微米之间变化。制备三元交互混合物,由CL、FL和BDP组成,乳糖与BDP的固定比例为67.5:1 w/w,但FL有两种浓度,即2.5%和5% w/w。使用三种组分不同的添加顺序进行混合,混合时间为两种(15分钟和60分钟)。制备由CL和BDP组成的二元混合物作为两个混合时间的对照,这些对照在BDP含量方面的变异系数(COV)<=5%。如果最终粉末通过先将CL与FL混合然后再与药物混合来制备,向二元制剂中添加FL会大大降低BDP的含量均匀度(混合15分钟后COV>20%)。然而,使用其他混合顺序制备的混合物,其BDP含量均匀度与二元混合物相似。所有含有2.5% FL的三元混合物在通过旋转吸入器以60 l min(-1)的流速雾化到双级液体冲击器后,始终产生显著更高(方差分析P<0.01)的BDP细颗粒分数(FPF,3.1 - 6.1%)和细颗粒剂量(FPD,13.6 - 30.1微克),高于二元混合物(FPF,0.3 - 0.4%;FPD,1.6 - 2.1微克)。混合顺序对使用15分钟混合时间制备的制剂中BDP的分散和解聚有显著(P<0.05)影响,但当混合时间延长至60分钟时,这种影响消失。BDP从三元混合物中的分散性始终高于二元混合物。通过向制剂中添加FL,干粉吸入器的BDP递送显著改善,而药物的含量均匀度没有大幅降低。